3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
13
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
40
Gemcitabine
37
Cisplatin
28
Carboplatin
17
enfortumab vedotin
15
Nivolumab
15
Mitomycin
14
atezolizumab
13
avelumab
12
Docetaxel
10
vinflunine
9
5-aminolevulinic acid hexyl ester
9
apaziquone
8
Paclitaxel
8
BCG Vaccine
7
durvalumab
6
Fluorouracil
6
Cystectomy
6
sacituzumab govitecan
4
Surgical Procedures, Operative
4
Drug Therapy
4
vofatamab
3
valrubicin
3
tisotumab vedotin
3
erdafitinib
3
cemiplimab
3
belinostat
3
Therapeutic Uses
3
Ramucirumab
3
Cystoscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urinary Bladder Neoplasms
×
AZD9833
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled